The FDA has approved Awiqli, the first once‑weekly long‑acting basal insulin, for adults with type 2 diabetes, which offers ...

Tirzepatide (Zepbound, Mounjaro) is a dual-agonist GLP-1 medication. It works like a GLP-1 agonist, but also targets a ...

Type 2 diabetes occurs when the body does not use insulin effectively or does not produce enough insulin to maintain healthy blood sugar levels. Medications aim to lower blood glucose, reduce A1C, and ...

The first-in-class injectable could be the next big thing in diabetes and obesity treatment.

The FDA approved Wegovy HD, a higher-dose semaglutide for weight loss in adults with obesity, offering greater weight ...

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated. (NewsNation) — An estimated 15.5 million U.S ...

West Pharmaceutical Services WST recently expanded its Dublin facility with a new 165,000 square foot building, significantly ...

(1,2) "Awiqli (R) is an important new option that meets a real need as the first FDA-approved, once-weekly basal insulin for adult patients with type 2 diabetes. It's helping to reframe what basal ...